On Friday, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) opened lower -3.20% from the last session, before settling in for the closing price of $1.25. Price fluctuations for ZNTL have ranged from $1.01 to $13.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 3.75% at the time writing. With a float of $55.63 million, this company’s outstanding shares have now reached $71.95 million.
The firm has a total of 166 workers. Let’s measure their productivity. In terms of profitability, gross margin is 97.6%, operating margin of -789.32%, and the pretax margin is -834.36%.
Zentalis Pharmaceuticals Inc (ZNTL) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Zentalis Pharmaceuticals Inc is 22.69%, while institutional ownership is 76.55%. The most recent insider transaction that took place on Apr 30 ’25, was worth 29,373. In this transaction Director of this company bought 21,000 shares at a rate of $1.40, taking the stock ownership to the 281,192 shares. Before that another transaction happened on Feb 06 ’25, when Company’s Chief Medical Officer bought 20,000 for $2.28, making the entire transaction worth $45,656. This insider now owns 36,629 shares in total.
Zentalis Pharmaceuticals Inc (ZNTL) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.51 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.04% during the next five years compared to -12.89% drop over the previous five years of trading.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Check out the current performance indicators for Zentalis Pharmaceuticals Inc (ZNTL). In the past quarter, the stock posted a quick ratio of 6.94. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.15, a number that is poised to hit -0.53 in the next quarter and is forecasted to reach -1.98 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Analysing the last 5-days average volume posted by the [Zentalis Pharmaceuticals Inc, ZNTL], we can find that recorded value of 0.72 million was lower than the volume posted last year of 1.36 million. As of the previous 9 days, the stock’s Stochastic %D was 47.16%. Additionally, its Average True Range was 0.09.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 8.68%, which indicates a significant decrease from 30.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.04% in the past 14 days, which was lower than the 103.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3702, while its 200-day Moving Average is $2.5477. Now, the first resistance to watch is $1.2317. This is followed by the second major resistance level at $1.2533. The third major resistance level sits at $1.2717. If the price goes on to break the first support level at $1.1917, it is likely to go to the next support level at $1.1733. Should the price break the second support level, the third support level stands at $1.1517.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
There are currently 71,952K shares outstanding in the company with a market cap of 87.06 million. Presently, the company’s annual sales total 67,430 K according to its annual income of -165,840 K. Last quarter, the company’s sales amounted to 26,870 K and its income totaled -47,470 K.
